No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRNA240705P126000
- 8.58
- -1.27-12.89%
15min DelayClose Jul 3 13:00 ET
8.58High8.58Low
8.58Open9.85Pre Close1 Volume125 Open Interest126.00Strike Price858.00Turnover76.64%IV-1.27%PremiumJul 5, 2024Expiry Date10.05Intrinsic Value100Multiplier1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.9499Delta0.0185Gamma11.42Leverage Ratio-0.1000Theta-0.0037Rho-10.85Eff Leverage0.0078Vega
Intraday
- 5D
- Daily
News
Targeting bird flu! The US government has allocated $176 million for the development of the Moderna vaccine.
Moderna has disclosed that the US government has allocated $176 million to Moderna to advance research on its bird flu vaccine. In March of this year, US officials reported the first case of H5N1 virus in cows, with at least 130 infected cows and three cases of human bird flu infection in 12 states since then.
Here's How Much $1000 Invested In Moderna 5 Years Ago Would Be Worth Today
Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 37.68% on an annualized basis producing an average annual return of 50.84%. Currently, Moderna has a market capitalization of
Moderna Given $176 Million to Advance Bird Flu Vaccine
A Fourth Dairy Worker Tests Positive for Bird Flu as Federal Response Ramps Up -- Barrons.com
By Josh Nathan-Kazis A Colorado dairy worker has tested positive for avian influenza, the Centers for Disease Control and Prevention said Wednesday afternoon, bringing the total number of farmers inf
GSK Will Pay Up to $1.5 Billion for CureVac's MRNA Vaccines -- Barrons.com
By Josh Nathan-Kazis The drugmaker GSK plunged into the messenger RNA-based vaccine market Wednesday, announcing it will buy the rights to experimental influenza and Covid-19 mRNA vaccines from the b
Moderna has been awarded $176 million by the US Department of Health for the development of a bird flu vaccine.
On July 3rd, Guolonghui reported that the Rapid Response Partnership Program (RRPV) of the U.S. Department of Health and Human Services provided Moderna with a project funding of $176 million to promote the development of bird flu vaccines based on mRNA technology, especially for the highly contagious H5 influenza virus. This virus not only causes serious illness in birds, but also poses the risk of transmission to humans. Moderna stated that the agreement with RRPV covers not only the current vaccine development, but also additional options prepared for future public health threats, demonstrating the company's forward-looking layout for future challenges.